OptiNose, Inc. (OPTN) earnings
OPTN earnings moved a median of 0.00% by the close. Quarterly and annual OPTN reports and results, each read against the price at its own news timestamp. Back to the OPTN overview →
20 measured OPTN earnings events.
Where these OPTN earnings landedvs 20 measured OPTN earnings reactions
| Middle 50% of OPTN earnings reactions | -5.66% to +2.42% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 OPTN earnings events with a measured close landed between -5.66% and +2.42%; 40% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q OptiNose, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +1.06% | |
| Form 10-K/A OptiNose, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.43% | +0.64% | |
| Form 10-K OptiNose, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.09% | +0.00% | |
| Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call | Press release | -1.05% | -3.68% | |
| Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million | Press release | -6.57% | +9.49% | |
| Form 10-Q OptiNose, Inc. For: Sep 30 | SEC filing · Form 10-Q | -15.87% | -13.04% | |
| Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights | Press release | -15.87% | -13.04% | |
| Optinose Announces Reporting Date for Third Quarter 2024 Financial Results | Press release | +0.75% | +5.97% | |
| Form 10-Q OptiNose, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.50% | +0.00% | |
| Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights | Press release | +2.50% | +0.00% | |
| Optinose Announces Reporting Date for Second Quarter 2024 Financial Results | Press release | +0.00% | +0.00% | |
| Form 10-Q OptiNose, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.86% | -2.59% | |
| Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights | Press release | +0.86% | -2.59% | |
| Optinose Announces Reporting Date for First Quarter 2024 Financial Results | Press release | +0.01% | +3.39% | |
| Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million | Press release | -8.87% | -27.02% | |
| Form 10-K OptiNose, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.19% | +2.38% | |
| Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results | Press release | +1.70% | +7.91% | |
| Form 10-Q OptiNose, Inc. For: Sep 30 | SEC filing · Form 10-Q | -6.52% | -11.59% | |
| Optinose Reports Third Quarter 2023 Financial Results and Operational Updates | Press release | -6.52% | -11.59% | |
| Optinose Announces Reporting Date for Third Quarter 2023 Financial Results | Press release | +0.84% | +2.52% |
Keep exploring
More OPTN: analyst actions → · SEC filings → · OPTN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Curis, Inc. (CRIS) | 205 | 0.00% | 45% |
| NovaBay Pharmaceuticals, Inc. (NBY) | 205 | -0.94% | 32% |
| ASPEN PHARMACRE HL UN/ADR (APNHY) | 204 | 0.00% | 15% |
| Benitec Biopharma Inc. (BNTC) | 203 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.